secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEOGENOMICS INC (NEO)
CIK:        0001077183
Form:       8-K
Filed at:   2024-02-20T23:59:59+00:00
Accession:  0001077183-24-000009
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeoGenomics Q4 revenue $156M (+12% YoY); FY loss narrows 39% to $88M; guides FY24 rev $650-660M
--------------------------------------------------------------------------------

- Q4 consolidated revenue $156M (+12% YoY); Clinical Services +20% to $130M, Advanced Diagnostics -17% to $25M.
- Q4 net loss $14M (improved from $23M loss in Q4'22); Adjusted EBITDA turned positive to $9M (vs -$1M).
- Full year revenue $592M (+16% YoY); net loss $88M (improved from $144M); Adjusted EBITDA positive $3M (vs -$48M).
- FY2024 guidance: revenue $650-660M (10-12% growth), net loss $(72)-$66M, Adjusted EBITDA $21-24M (600-700% improvement).
- Cash and marketable securities $415M at year-end; no debt or dividend changes reported.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1077183/000107718324000009/0001077183-24-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1077183/000107718324000009/neo-20240220.htm
  HTML page:      https://secwatch.observer/filing/0001077183-24-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer